Neurogene (NGNE) shares slumped 34% pre-bell Tuesday, a day after the company said it will not move forward with its Batten disease gene therapy program.
1847 Holdings (EFSH) shares fell 30%, paring Monday's rally.
General American Investors (GAM) shares were down 18% following a muted session.